K. Weigang-Koehler

Tumor-promoting Versus Tumor-antagonizing Roles of &ggr;&dgr; T Cells in Cancer Immunotherapy: Results From a Prospective Phase I/II Trial

J. Becker, H. Einsele, B. Kimmel, 2012, Journal of immunotherapy.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Peter Neuhaus, Jan Langrehr, Karsten Ridwelski, 2007, JAMA.

Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

J. Rüssel, M. Scheulen, L. Bergmann, 2013 .

Reduction of HLA-DR+ Lymphocytes after Treatment with Enzastaurin in Patients with Metastatic Thyroid Cancer

M. Wilhelm, M. Lahn, A. Hanauske, 2008, Chemotherapy.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

H. Oettle, I. Schmidt-Wolf, K. Ridwelski, 2007 .

Tumor-promoting Versus Tumor-antagonizing Roles of &ggr;&dgr; T Cells in Cancer Immunotherapy: Results From a Prospective Phase I/II Trial

J. Becker, H. Einsele, B. Kimmel, 2012, Journal of immunotherapy.

Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial

V. Heinemann, G. Schlimok, R. Schlag, 2005 .